A new research project based in Denmark is to examine whether changes in the human microbiome can potentially cause cardiometabolic diseases such as obesity, type 2 diabetes and cardiovascular disease. Announced on 22 May, the project will be initially financed by the Novo Nordisk Foundation, a philanthropic organisation whose assets are managed by Novo Holdings. Novo Holdings is the controlling shareholder of Novo Nordisk A/S, developer of the obesity drugs liraglutide and semaglutide.
